Stocks Are Taking a Hit Once More, But There's No Need to Panic.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy GEHC?
Source: Barron's
- Market Condition: The stock market is experiencing a slowdown, but it is not in a severe downturn.
- Investor Sentiment: Investors are expressing concerns regarding the valuations of leading tech and artificial intelligence stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 83.920
Low
80.00
Averages
92.25
High
105.00
Current: 83.920
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Technological Innovation: The FDA has recently approved GE HealthCare's next-generation SIGNA MRI technology, which includes SIGNA Sprint and Freelium technology aimed at reducing helium dependency, thereby enhancing sustainability and cost-effectiveness in MRI technology.
- Performance Enhancement: The newly launched SIGNA Bolt 3T MRI scanner, recognized in the FDA clearance, promises a 65% reduction in peak power demand and a 34% reduction in minimum equipment room space, showcasing GE HealthCare's commitment to innovation and environmental sustainability.
- Stock Performance Analysis: GE HealthCare Technologies' shares are currently priced at $84.24, trading 4.9% above its 20-day SMA and 6.6% above its 100-day SMA, despite an 8.59% decline over the past 12 months, indicating a potential bullish trend in recent performance.
- Optimistic Earnings Expectations: The upcoming earnings report on April 29, 2026, is anticipated to be a major catalyst for the stock, with analysts estimating an EPS of $1.06 and revenue of $5.03 billion, reflecting a positive outlook on the company's financial performance.
See More
- New Technology Launch: GE HealthCare announced FDA clearance for the SIGNA Sprint with Freelium 1.5T and SIGNA Bolt 3T MRI systems, marking a significant advancement in the company's innovation strategy in the MRI sector aimed at enhancing image quality and clinical efficiency.
- Sustainable Design: The SIGNA Sprint features helium-free technology with less than 1% usage, providing exceptional image quality without increasing energy consumption, enabling flexible installation to expand healthcare access in remote areas, addressing the rising demand for imaging services.
- AI-Driven Workflow: The SIGNA One ecosystem integrates multiple AI solutions designed to improve MRI operational efficiency, reduce variability, and enhance the experience for both patients and technologists, helping healthcare providers maintain efficiency amid increasing imaging volumes.
- Market Leadership: Since its spinoff in 2023, GE HealthCare has significantly invested in MRI, and the FDA approvals not only strengthen its competitive position but also highlight its strategic focus on innovation, sustainability, and productivity.
See More
- Portfolio Adjustment: Trian Fund Management's latest 13F filing for Q4 2025 reveals an increase in stakes in major industrial and healthcare companies while trimming cyclical financial positions, indicating a cautious outlook on the economic landscape.
- Shift in Acquisition Strategy: Nelson Peltz hinted at a potential shift towards direct buyouts rather than traditional proxy fights, suggesting that this strategy could enable faster implementation of business strategies and enhance investment returns.
- Strong Performance of GE Aerospace: One of Trian's top bets, GE Aerospace, has benefited from robust demand in defense and commercial aviation, with strong order backlogs and ramped-up engine production, leading to a stock increase of over 55% in the past year, closing up 3.7% at $327.08.
- Market Trend Analysis: Benzinga's data indicates favorable price trends for GE Aerospace's stock across various time periods, along with strong Momentum and Quality rankings, reflecting sustained market confidence in the company's future prospects.
See More
- Dividend Declaration: GE HealthCare Technologies announced a cash dividend of $0.035 per share for Q1 2026, payable on May 15, 2026, to shareholders of record as of April 3, 2026, maintaining the same amount as Q4 2025, which reflects the company's stable cash flow and commitment to shareholder returns.
- Launch of ReadyFix: On February 9, GE HealthCare introduced ReadyFix, a remote fleet management solution designed to help healthcare systems monitor and support the uptime of connected medical devices, collecting real-time data for remote diagnostics and maintenance, thereby enhancing device performance.
- Reducing Downtime: The ReadyFix solution aims to minimize device disruptions and downtime, ensuring consistent performance of ECG workstations critical for cardiac care, particularly in light of the increasing complexity of hospital device fleets.
- Alleviating Maintenance Strain: GE HealthCare's management noted that as the number of connected devices in hospitals grows, biomedical teams face operational strain from maintenance workloads, and ReadyFix's standardized configurations and remote update capabilities will help alleviate this pressure and improve operational efficiency.
See More
- Quarterly Dividend Announcement: GE HealthCare Technologies has declared a quarterly dividend of $0.035 per share, payable on May 15, reflecting the company's stable cash flow and commitment to shareholder returns.
- Record Date for Shareholders: The record date for this dividend is April 3, with the ex-dividend date also set for April 3, ensuring eligible shareholders receive their dividends promptly, which enhances investor confidence.
- Future Growth Expectations: GE HealthCare anticipates an 8% to 12% growth in EPS for 2026, alongside a target of $1.7 billion in free cash flow, indicating strong potential driven by new product launches.
- Positive Market Reaction: Following fourth-quarter results that exceeded expectations, GE HealthCare's stock price has risen, reflecting market optimism regarding the company's future growth prospects and further solidifying its competitive position in the healthcare technology sector.
See More









